Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors

Citations Over TimeTop 18% of 2008 papers

Abstract

We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.

Related Papers

• → VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy(2006)214 cited
• → VEGF receptor trafficking in angiogenesis(2009)38 cited
• → Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling(2020)38 cited
• → Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-α/ϵ (PKCα/ϵ)-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A(2004)49 cited
• → High levels of HtrA4 detected in preeclamptic circulation may disrupt endothelial cell function by cleaving the main VEGFA receptor KDR(2019)16 cited